Document is current
Any future updates will be listed below
-
Authors
Veyrier, Clair-Antoine https://orcid.org/0000-0003-3497-0382
Vermersch, Patrick https://orcid.org/0000-0003-0997-8817
Casez, Olivier https://orcid.org/0000-0002-8261-5302
Heinzlef, Olivier https://orcid.org/0000-0002-4634-8542
Payet, Marianne https://orcid.org/0009-0008-8375-7530
Luciani, Laura
Collongues, Nicolas https://orcid.org/0000-0002-3683-5582
Duracinsky, Martin https://orcid.org/0000-0003-3901-2255
-
Funding
Funding for this research was provided by:
Merck Healthcare KGaA
- License Information
-
More Information
Article History
Received: 12 March 2026
Accepted: 6 May 2026
First Online: 5 June 2026
Declarations
:
: Laura Luciani and Marianne Payet are employees of Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA. Olivier Casez: Honorarium Biogen, Sanofi-Genzyme, Novartis, Merck, Roche, Janssen, Juvisé, Alexion, Coloplast and Amgen. Patrick Vermersch: Honorarium Biogen, Sanofi Genzyme, Novartis, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Roche, Imcyse, AB Science, Janssen, Ad Scientiam and BMS. Nicolas Collongues: Honorarium Alexion, Biogen Idec, Bristol-Myers Squibb, Horizon Therapeutics, Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA, Novartis, Roche, Sanofi-Genzyme. Olivier Heinzlef: Honorarium Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA, Almirall, Bayer Schering, Biogen Idec, Genzyme, Janssen Cilag, Novartis, Roche, Sanofi, Teva. Martin Duracinsky: Honorarium Merck Santé S.A.S. Clair-Antoine Veyrier declares no conflicts of interest.
: The study was approved on October 29, 2024 (CER-2024-268) by Institutional Review Board Comité d’Ethique de la Recherche (CER) Paris Nord (IRB 00006477) of HUPNVS, Paris Cité University, AP-HP. All subjects provided informed consent to participate in the study.
